Lumida
/CRVS
⌘K
Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CRVS
$14.65USD↑+3.17%+0.45 today

MARKET CAP

1.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$6
$27

AI Summary

Stalk
StalkMedium

CRVS is consolidating in a Stage 4 base at the rising trendline and 200-SMA, offering medium-term bullish skew near support. However, EMAs are tightly clustered with a recent 9/20 crossover and RSI is neutral, indicating no clear short-term edge. Patience is warranted: defer engagement until a deeper pullback into the trendline/200-SMA zone is tested and accepted before committing.

  • ↑Cash $215.2 M (up from $56.8 M) funds ops through Q2 2028
  • ↑R&D spend up 103% YoY to $16 M signals strong trial backing
  • ↓Q2 net loss $18 M vs $8 M year-ago strains cash flow
Full analysis →

Buying

6

institutions

Selling

4

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY7.14 M106.65 M+978.39 K+18.3%0.00%
PA

Perceptive Advisors LLC

Q2 2026

SELL2.67 M39.85 M+-1.92 M-40.6%0.60%
MM

Millennium Management LLC

Q2 2026

BUY1.05 M15.66 M+181.62 K+23.5%0.01%
CA

Citadel Advisors LLC

Q2 2026

BUY1.04 M15.58 M+130.13 K+16.7%0.00%
EP

Eversept Partners, LP

Q2 2026

BUYNEW747.99 K11.18 M+747.99 K+0.0%0.58%
BH

Brevan Howard Capital Management LP

Q2 2026

BUY250.29 K3.74 M+82.32 K+52.2%0.03%
JC

Jpmorgan Chase & Co

Q2 2026

SELL141.99 K2.06 M+-3.17 K+5.7%0.00%
AC

Adar1 Capital Management, LLC

Q2 2026

BUY117.10 K1.75 M+29.20 K+36.0%0.08%
VI

Voloridge Investment Management, LLC

Q2 2026

SELL0.000.00+-278.01 K-100.0%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL0.000.00+-81.31 K-100.0%0.00%